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ARTICLE
Paracrine effect of regulatory T cells promotes
cardiomyocyte proliferation during pregnancy and
after myocardial infarction
Serena Zacchigna1,2, Valentina Martinelli3, Silvia Moimas 2,3, Andrea Colliva1, Marco Anzini2, Andrea Nordio2,
Alessia Costa1, Michael Rehman1, Simone Vodret1, Cristina Pierro1, Giulia Colussi 3, Lorena Zentilin3,
Maria Ines Gutierrez3, Ellen Dirkx3, Carlin Long3, Gianfranco Sinagra2, David Klatzmann4,5 & Mauro Giacca 2,3
Cardiomyocyte proliferation stops at birth when the heart is no longer exposed to maternal
blood and, likewise, to regulatory T cells (Tregs) that are expanded to promote maternal
tolerance towards the fetus. Here, we report a role of Tregs in promoting cardiomyocyte
proliferation. Treg-conditioned medium promotes cardiomyocyte proliferation, similar to the
serum from pregnant animals. Proliferative cardiomyocytes are detected in the heart of
pregnant mothers, and Treg depletion during pregnancy decreases both maternal and fetal
cardiomyocyte proliferation. Treg depletion after myocardial infarction results in depressed
cardiac function, massive inflammation, and scarce collagen deposition. In contrast, Treg
injection reduces infarct size, preserves contractility, and increases the number of pro-
liferating cardiomyocytes. The overexpression of six factors secreted by Tregs (Cst7, Tnfsf11,
Il33, Fgl2, Matn2, and Igf2) reproduces the therapeutic effect. In conclusion, Tregs promote
fetal and maternal cardiomyocyte proliferation in a paracrine manner and improve the out-
come of myocardial infarction.
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A major, still unresolved issue in the cardiac regenerationfield is the reason why the proliferative capacity of car-diomyocytes (CMs) undergoes a grinding halt early after
birth1. Besides major hemodynamic and biochemical events
occurring after birth, one major change is a sudden lack of
exposure to the maternal circulation, suggesting that circulating
cells or serum factors might be involved in the exit of CMs from
the cell cycle. In particular, regulatory T cells (Tregs) could play a
role in this process, as they are expanded in the mother to pro-
mote maternal immune tolerance toward the fetus2. Tregs are
CD4+ T cells expressing the transcription factor Forkhead box
protein 3 (FOXP3), in addition to specific anti-inflammatory
cytokines, such as interleukin-10 (IL-10) and transforming
growth factor-β (TGF-β), which dampen an excessive effector
immune response3. At the onset of pregnancy, a profound
modulation of the maternal immune response occurs, which
entails CD4+ CD25+ Treg cell activation and expression of
variety of molecules (TGF-β, IL-10, IL-8, and IL-2 receptor,
among others), which will blunt the immune response of the
mother and license development of the semi-allogeneic fetus4. In
addition to immune suppressive function, recent reports have
revealed that Tregs also control non-immunological processes,
including visceral adipose metabolism5,6 and muscle repair7.
Moreover, an involvement of Tregs in the susceptibility and
outcome of ischemic heart disease was described in both
experimental models and in humans8–10.
More recently, a beneficial effect of Tregs in improving the
healing after myocardial infarction by modulating monocyte/
macrophage polarization was reported11.
Myocardial repair following ischemic injury involves a series of
inflammatory events. A transient recruitment of circulating
neutrophils and monocytes is followed by an intense macrophage
infiltration. Within days, macrophages progressively shift from a
pro-inflammatory, M1-type phenotype, required for the
clearance of necrotic and apoptotic debris, to an anti-inflamma-
tory, M2-type phenotype, exhibiting various pro-regenerative
functions, such as matrix remodeling and promotion
of angiogenesis12. Tregs have been shown to induce M2-type
macrophage polarization within the healing myocardium, asso-
ciated with myofibroblast activation and increased expression of
monocyte/macrophage-derived proteins, which foster wound
healing11.
Here, we explore the possibility that Tregs directly regulate CM
proliferation and might thus be used to stimulate myocardial
repair after an acute ischemic damage. Our results show that the
medium conditioned by Tregs promotes CM proliferation,
similar to the serum from pregnant animals. Proliferative CMs
are detected in the heart of pregnant mothers and Treg depletion
during pregnancy decreases both maternal and fetal cardiomyo-
cyte proliferations. After myocardial infarction, Treg depletion
results in depressed cardiac function, massive infiltration of
inflammatory cells and scarce collagen deposition into the scar. In
contrast, Treg injection reduces infarct size, preserves con-
tractility and increases the number of proliferating CMs. The
overexpression of six factors secreted by Tregs (Cst7, Tnfsf11,
Il33, Fgl2, Matn2, and Igf2) reproduces their therapeutic effect.
Thus, Tregs promote fetal and maternal CM proliferations in a
paracrine manner and improve the outcome of myocardial
infarction.
Results
Factors secreted by Tregs promote cardiomyocyte prolifera-
tion. We collected serum from mice at post-natal day 0 (neonatal
serum, NS), 2 months old adult mice (adult serum, AS), and
pregnant female mice at E15, namely 2 weeks after the detection
of the vaginal plug marking successful mating (pregnant serum,
PS). The sera were added to primary cultures of neonatal rat
ventricular CMs, containing >90% CMs, together with 5-
ethynyl29-deoxyuridine (EdU), a uridine analog that is incorpo-
rated into newly synthesized DNA. After 2 days, the cells were
stained for sarcomeric α-actinin to distinguish CMs and for EdU
incorporation. The serum from pregnant animals significantly
stimulated CM proliferation when compared to CMs treated with
neonatal or adult sera (Fig. 1a, b).
To start assessing the possible contribution of Tregs to this
mitogenic activity, we transiently depleted the Treg population in
pregnant CD1 animals by injecting an anti-CD25 antibody
(PC61) on days E10 and E15, as indicated in Fig. 1c (n= 4 per
group). Treg depletion in pregnant animals is known to interfere
with maternal tolerance and to increase resorption rate during the
implantation phase and early pregnancy, but not in the late stage
of allogeneic pregnancy13. Therefore, we started depleting Tregs
in pregnant mice starting from E10, in order to minimally
interfere with embryonic viability. Efficacy of depletion was
assessed by flow cytometry by quantifying the number of CD25+
cells in lymph nodes. As shown in Supplementary Fig. 1a, c,
treatment with PC61 antibody eliminated CD25+ cells; the
depletion was sustained for 7 days. Of notice, the serum from
pregnant animals upon Treg depletion (TDPS in Fig. 1a, b)
resulted in the complete loss of the pro-proliferative activity on
neonatal rat ventricular CMs.
We then determined the effect of Treg depletion in the heart of
developing embryos, by either using the PC61 antibody or
administering diphtheria toxin to DEREG mice, which carry a
diphtheria toxin receptor (DTR)-eGFP transgene under the
control of the Foxp3 promoter, thereby allowing specific
depletion of Tregs by application of diphtheria toxin (DT) (n
= 4 per group). Also in this case, the depletion of eGFP+CD25+
cells was evident a few days after toxin injection and lasted for
about 1 week (Supplementary Fig. 1b, c). No increase in either the
expression levels of pro-inflammatory molecules or the number
of CD45+ leukocytes was observed in the TD embryonic hearts
compared to controls, ruling out any major autoimmune
response upon Treg depletion (Supplementary Fig. 1b, e). Starting
from day E11, the same animals were administered EdU
intraperitoneally every 24 h until day E18, when CM proliferation
was assessed in the embryonic heart (n > 10 per group; Fig. 1c).
Analysis of EdU incorporation revealed a marked reduction in
the number of EdU+/α-actinin+ CMs in depleted animals in both
models of Treg depletion (Fig. 1d–f). A detailed analysis of CM
proliferation rate was performed on atria, septum, right and left
ventricle of the fetal heart, using both α-actinin and PCM1
antibodies to label CMs. In our experience, the combined use of
these two markers allows for a reliable identification of CMs,
since the use of α-actinin alone can bias the assignment of a
proliferative nucleus to a CM, while the use of PCM1 alone can
instead mislead identification, as several neonatal cardiac
fibroblasts score positive, while some adult CM nuclei score
negative for this marker (Supplementary Fig. 2). Comparable
results were obtained using both CM-specific markers and
confirmed a significant reduction in the number of EdU+/α-
actinin+ and EdU+/PCM1+ CMs in all cardiac regions (Fig. 1f,
left and right panels, respectively, P < 0.05, as determined by one-
way analysis of variance and Bonferroni post hoc test). No major
differences were observed in the proliferation rate between the
four cardiac compartments.
To obtain further evidence that the pro-proliferative effect
exerted by the serum of pregnant animals in vitro and in vivo was
dependent on molecules secreted by Tregs, we collected the
medium conditioned by Tregs cultured on CD3-coated plates in
the presence of IL-214, and added it to cultures of neonatal rat
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ventricular CMs. These primary cultures also contain a few non-
CM cells, of which >99% are fibroblasts15. Cell proliferation was
assessed by EdU incorporation, as well as by staining for Ki67 and
histone H3 phosphorylated on serine10 (H3PS10), which
represent markers of the all active phases of the cell cycle and
of late G2/mitosis, respectively. Exposure to the Treg-condition
medium significantly increased the percentage of all the three
proliferation markers in CMs but not in fibroblasts (Fig. 2a–d).
To demonstrate that the increase in CM DNA replication
eventually resulted in cell division, we stained cells for Aurora B
kinase. Treatment with Treg-conditioned medium significantly
increased the number of cells presenting Aurora B localized at
midbodies, which are transient structures formed during
cytokinesis (Fig. 2a, e).
Taking these data collectively, it can be concluded that Tregs
secrete soluble factors that promote embryonic and neonatal CM
proliferation in vitro and in vivo.
Tregs contribute to increased heart size during pregnancy.
Inspired by the evidence that Tregs exert a pro-proliferative effect
on embryonic and neonatal CMs, we wondered whether
a similar activity might occur in the heart of pregnant animals, in
which the Treg pool is expanded to secure maternal tolerance
toward fetal antigens. It is well known that the heart experiences
an increase in size during pregnancy. This phenomenon
has been traditionally ascribed to a reversible, compensatory
enlargement in CM size in response to the increased circulating
volume occurring in pregnant organisms and therefore considered
an example of transient physiological hypertrophy. We
hypothesized that an increase in CM number, in addition to their
size, might contribute to the gross enlargement of the heart during
pregnancy.
First, we confirmed that both heart size and the percentage of
circulating Tregs increased during pregnancy; while the heart
progressively enlarged during the whole duration of pregnancy
until delivery, the percentage of Tregs peaked at E12 and then
decreased at subsequent times (n= 5; Fig. 3a–c). CM cross-
sectional area was also significantly increased at delivery (Fig. 3d),
despite pregnancy is known to increase CM length more than
their diameter16.
We then assessed CM proliferation by counting the number of
EdU+ CMs in the hearts of pregnant animals, repeatedly injected
with EdU starting from E10, as described in Fig. 1c. We found
that the number of EdU+ CMs in the mothers’ hearts was
increased during pregnancy and at the time of delivery; in
particular, proliferation peaked at E12 (Fig. 3e, f and Supple-
mentary Fig. 3a), at the time when Tregs number was the highest
in the maternal circulation (Fig. 3c). A few CMs in E12 hearts
showed positivity for the proliferation marker Ki67 (Supplemen-
tary Fig. 3b) and AuroraB localization at midbodies, which
indicated passage through mitosis and was never observed in
control CMs (Fig. 3g, h). Of notice, the number of proliferating
CMs, detected by both EdU incorporation and AuroraB staining
was reduced in the heart of Treg-depleted, pregnant animals
(Supplementary Fig. 3c, d).
Thus, CM proliferation occurs in the heart of pregnant
animals, at least in part sustained by Tregs, contributing to the
gross increase in heart size during pregnancy.
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Fig. 1 Tregs in the maternal serum promote CM proliferation. a Rat neonatal CMs were exposed to the serum collected from neonatal (NS), adult (AS),
pregnant (PS) and Treg-depleted pregnant (TDPS) animals and proliferation measured by EdU incorporation. Nuclei are stained blue with 4’-6-diamidino-
2-phenylindole (DAPI) and CMs green by anti-α-actinin antibodies. Red nuclei indicate EdU incorporation. Scale bar, 100 μm. Insets shows a higher
magnification of the area defined by the white dotted line. b Quantification of EdU+ CM nuclei (% of total CMs) after exposure to the different sera. c
Outline of the experimental procedure followed for Treg depletion in vivo in pregnant animal. The Treg-depleting agent, either PC61 antibodies in CD1 mice
or Dyphteria Toxin (DT) in DEREG mice, was administered i.p. to the pregnant mother at embryonic days 10 (E10) and 15 (E15). EdU was administered i.p.
every day from E10 to E18, when embryos were removed for histological analysis. d Quantification of EdU+/ α-actinin CM nuclei (% of total CMs) in the
heart of embryos harvested from either control (white bars) or Treg-depleted (gray bars) mothers, in the two models of Treg depletion described in panel
(c). e Longitudinal section of a whole E18 heart, in which nuclei are stained blue with DAPI, CMs green by anti-α-actinin antibodies and EdU incorporation is
shown in red. Scale bar, 1 mm. f High magnification images of the indicated regions of embryonic hearts from control (C) and Treg-depleted (TD) mothers,
in which nuclei are stained blue with DAPI, CMs green by either anti-α-actinin or PCM1 antibodies and EdU incorporation is shown in red. RV: right
ventricle, LV: left ventricle. White numbers indicate the percentage of EdU+ CMs in each cardiac region. Scale bar, 20 μm. Values in (b) and (d) are mean
± s.e.m., n≥ 3 biological replicates. One-way analysis of variance and Bonferroni/Dunn’s post hoc tests were used to compare multiple groups (b). Pairwise
comparison was performed with the Student’s t-test (d). **P < 0.01, ***P < 0.001 relative to control
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Endogenous Tregs protect the heart after myocardial infarc-
tion. Since the previous results were consistent with effect of
Tregs in inducing CM proliferation in both developing and adult
hearts, we explored whether Tregs might also exert a beneficial,
pro-regenerative role in adulthood following myocardial infarc-
tion (MI). By exploiting the presence of eGFP+ Tregs in
untreated DEREG mice, we analyzed the endogenous recruitment
of Tregs at different time points after the induction of MI by
permanent ligation of the left anterior descending coronary artery
(n= 16 per group; 4 animals per time point). A significant
number of Tregs was detected in the region of the heart sur-
rounding the ischemic zone, already a few hours after coronary
artery ligation; these cells persisted in the infarcted area for at
least 7 days (Supplementary Fig. 4a, b). Treg recruitment at the
site of MI was also confirmed by the increased level of Foxp3
mRNA at the same time points (Supplementary Fig. 4c). In line
with the presence of Tregs in the ischemic heart, the expression of
TGF-β and IL-10, two factors abundantly produced by Tregs, was
significantly increased during the first week after coronary artery
ligation and, particularly, a few hours after the ischemic insult
(Supplementary Fig. 4d).
We then assessed the outcome of MI in CD1 mice that had
been depleted of Tregs using an anti-CD25 antibody 5 days in
advance of and 30 days after surgery (n= 12 per group).
Prolonged Treg depletion increased the number of major lethal
events, such as apical aneurysms and cardiac ruptures,
resulting in a net increase in mortality in the Treg-depleted
group compared to not depleted animals (Fig. 4a, b). As
evaluated by ultrasound imaging in surviving mice, left
ventricular ejection fraction (LVEF, Fig. 4c), fractional short-
ening, end-systolic anterior wall thickness, thickening, and
internal diameter (Supplementary Fig. 5), were mildly but
consistently more compromised over time in Treg-depleted mice.
Morphometric analysis of the infarcted hearts confirmed the
presence of larger infarcts in Treg-depleted animals (Fig. 4d, e).
At histological examination, Treg depletion resulted in a
massive accumulation of CD45+ inflammatory cells (Fig. 4f, g),
which could have determined looser scars and propensity to
rupture. No significant changes in the extent of cell death were
detected in Treg-depleted hearts compared to controls (Supple-
mentary Fig. 6).
To better investigate the effect of Tregs in the fibrotic response,
we performed MI and Treg depletion in Collα1(I)-EGFP mice, in
which EGFP expression is confined to fibroblasts17. Both the
number of EGFP+ fibroblasts (Fig. 4h, i) and the intensity of
EGFP expression, which is a surrogate indicator of collagen
expression (Fig. 4h, j), were significantly reduced in Treg-depleted
mice.
Collectively, these data are consistent with the conclusion that
Tregs exert a protective role in MI healing by resolving
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inflammation and improving collagen deposition, thereby
protecting from cardiac rupture and preserving cardiac function.
Treg injection at the site of MI promotes CM proliferation. To
better discriminate between the immuno-modulatory and the
pro-proliferative activities of Tregs after MI, we assessed their
effect in mouse models of both ischemia-reperfusion and per-
manent coronary artery ligation (n= 8 per group), which better
reproduces the clinical condition and is associated to a different
pattern of cytokine expression and leukocyte recruitment to the
heart12,18. For both experimental approaches, we purified EGFP+
Tregs from DEREG mice by cell sorting (purity of sorting was
92% as shown in Supplementary Fig. 7). Immediately after iso-
lation, we injected 1.5 × 105 cells in the peri-ischemic area of the
heart of C57BL/6 syngeneic mice at the time of coronary artery
ligation. After 40 min of ischemia, the artery was made patent
again by surgical removal of the wire. The injected Treg cells
engrafted into the recipient heart and were still present at day 3
after injection, as determined by direct EGFP localization and
anti-EGFP immunostaining (Fig. 5a). Treg supplementation
resulted in reduced infarct size (Fig. 5b), associated with
improved cardiac function up to 3 months after MI (Fig. 5c).
We then assessed the effect of the same number of Tregs after
permanent coronary artery ligation. Also in this case, Treg
supplementation was effective in preserving LVEF (Fig. 5d), as
well as other parameters of cardiac function, such as end-systolic
anterior wall thickness, thickening and internal diameter
(Supplementary Fig. 8).
Based on the previous evidence that Tregs promote CM
proliferation during embryonic development and early post-natal
life, we scored the presence of proliferating CMs in a subgroup of
animals that underwent MI, followed by Treg injection and EdU
administration every other day for 2 weeks. The number of EdU+
CMs in the peri-infarct region was almost negligible in control
animals and significantly increased upon Treg supplementation
(Fig. 5e–g). Of notice, we could detect a few Tregs still present in
the heart at 2 weeks after injection, in close proximity to EdU+
CMs (Fig. 5h).
We also performed MI in genetically modified animals
presenting various impairments in the immune function,
such as athymic Nude-Foxn1 (lacking T cell activity), Fox Chase
SCID (lacking T and B cells), and Fox Chase SCID BEIGE
(presenting T and B cell deficiency and diminished NK cell
activity) mice. In all these immunodeficient mice, we could not
detect changes in the outcome of MI (Supplementary Fig. 9a–c)
nor in increased EdU incorporation (Supplementary Fig. 9d),
indicating that the immune system does not play a major role in
this setting, and likewise indicating that the effect of Tregs in
improving MI outcome is rather dependent on their capacity to
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induce CM proliferation rather than to modulate the immune
response.
Thus, the injection of an extra-amount of Tregs at the site of
cardiac ischemia exerts a beneficial effect on lesion healing, at
least in part by sustaining CM proliferation and independent
from their immunosuppressive function.
Six secreted proteins surrogate the mitogenic effect of Tregs.
To identify putative Treg-secreted factors responsible for the
observed proliferative effect, we performed an in silico analysis
and compared the transcriptome of CD4+/CD25+ Tregs with
that of CD4+/CD25− lymphocytes from the GEO database
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE4571).
We selected 12 secreted factors, which were abundantly expressed
by Tregs but not by CD4+/CD25− lymphocytes, of which an ORF
clone was available and suitable for cloning into an AAV plasmid
(Table 1). First, we tested the potential of each factor to
individually promote the proliferation of cultured CMs. To obtain
an enriched source of each factor, we transfected CHO cells with
each of the encoding plasmids and, after 48 h, we collected the
serum-free conditioned medium. The 12 supernatants, together
with a control medium, collected from CHO cells transfected with
an empty plasmid (pGi), were added to neonatal rat CMs, fol-
lowed by analysis of EdU incorporation. We identified six
secreted factors that were individually able to increase CM pro-
liferation, shown as black bars in Fig. 6a. These included Cst7,
Tnfsf11, Il33, Fgl2, Matn2, and Igf2. Based on these results and to
investigate potential synergy between the identified factors, we
pooled either all the 12 supernatants (Pool12) or those corre-
sponding to the six factors that were active individually (Pool6).
We found that Pool6 was superior to any individual factor and
that no further improvement was obtained by the inclusion of all
12 factors (Fig. 6a, b).
We moved on by testing the potential of the Treg-derived
soluble factors to surrogate the protective effect exerted by the
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control mice and in mice depleted of Tregs using an anti-PC61 antibody. Scale bar, 1.5 mm. b Quantification of the number of mice experiencing aneurysm
formation, cardiac rupture or death during the follow-up of the study (3 months) in the control (C) and Treg-depleted (TD, gray bars) groups. c US imaging
analysis of the left ventricular ejection fraction of control (C, circles) and Treg-depleted (TD, squares) mice at 1, 4, and 12 weeks (W) after myocardial
infarction. d Representative images of whole transverse sections after Azan Trichromic staining of hearts of control (C) and Treg-depleted (TD) animals.
Fibrotic areas are stained in gray/blue. Scale bar, 1 mm. e Quantification of infarct size (fibrotic area in D), expressed as percentage of the left ventricular
area in control (C) and Treg-depleted (TD) mice at 3 months after myocardial infarction. f Quantification of CD45+ cells in the scar region of control (C)
and Treg-depleted (TD) mice (% of total nuclei per field) at 1 month after myocardial infarction. g Heart sections from control (C) and Treg-depleted (TD)
animals stained by anti-CD45 pan leukocyte antibodies (red). Nuclei are stained blue with DAPI. Scale bar, 25 μm. h Representative images of heart
sections at 1 month after myocardial infarction in control (C) and Treg-depleted (TD) Collα1(I)-EGFP mice, showing green fibroblasts and nuclei stained
with DAPI. Scale bar, 100 μm. i, j Quantification of the number of EGFP+ fibroblasts (i) and EGFP fluorescence intensity (j) in the scar region of control (C)
and Treg-depleted (TD) Collα1(I)-EGFP mice (% of total nuclei per field) at 1 month after myocardial infarction. All values are mean ± s.e.m., each dot
indicates a biological replicate; n= 7 biological replicates in (b). Pairwise comparison was performed with the Student’s t-test (e, f, i, j). Two-way ANOVA
for repeated measurements was used in (c). *P < 0.05, **P < 0.01, relative to control
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whole cells. We produced AAV9 vectors for the in vivo
expression of the factors contained in both Pool6 and Pool12
and injected them in the peri-ischemic area of the heart of mice at
the time of coronary artery ligation (n= 8 per group). An AAV9
vector not coding for any protein was used as a control. All mice
received EdU throughout the duration of the experiment. Cardiac
function was assessed by echocardiography over time, followed by
morphometric and histological analysis. Both assessments
Table 1 Secreted proteins highly expressed by Treg cells compared to CD4+/CD25− cells
Gene symbol Gene name Relative expression (Treg over CD25−) Localization
Fgl2 Fibrinogen-like protein 2 6.820291067 Extracellular space
Matn2 Matrilin 2 6.469789887 Extracellular space
Tnfsf11 Tumor necrosis factor (ligand) superfamily, member 11 5.290882688 Extracellular space
Prss8 Protease, serine, 8 (prostasin) 4.66635417 Extracellular space
Cst7 Cystatin F (leukocystatin) 4.397173444 Extracellular space
Igfbp3 Insulin-like growth factor binding protein 3 4.226069724 Extracellular space
Il33 Interleukin 33 4.18511797 Extracellular space
Igf2 Insulin-like growth factor 2 4.111991921 Extracellular space
Cfhr1 Complement factor H-related 1 3.921560832 Extracellular space
Lta Lymphotoxin A 3.834880388 Extracellular space
Hapln2 Hyaluronan and proteoglycan link protein 2 3.771416801 Extracellular space
C2 Complement component 2 (within H-2S) 3.660525412 Extracellular space
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Fig. 5 Treg administration improves the outcome of myocardial infarction. a Tregs sorted by DEREG mice were injected into the border region of the
myocardial infarction and visualized as EGFP+ cells in heart section at day 3 after surgery, detecting either the endogenous green fluorescence (upper
panel) or using anti-EGFP antibodies (purple, lower panel). Scale bar, 25 μm. b Quantification of infarct size expressed as percentage of the left ventricular
area in control (C, circles) and Treg-injected (Treg, squares) mice at 3 months after myocardial infarction. c US imaging analysis of the left ventricular
ejection fraction of control (C) and Treg-injected (Treg) mice at 1, 4, and 12 weeks (W) after 40min (min) of coronary artery ligation followed by vessel
reperfusion. d US imaging analysis of the left ventricular ejection fraction of control (C) and Treg-injected (Treg) mice at 1, 4, and 12 weeks (W) after
permanent ligation of the left descendent anterior (LAD) coronary artery. e Sections of the heart of Treg-injected mice, showing EdU incorporation (stained
red) in the nuclei of CMs (stained green by anti-α-actinin antibodies). Scale bar, 100 μm. f Quantification of the EdU incorporation (% of total CM nuclei) in
CMs in control (C) and Treg-injected (Treg) hearts at 15 days after permanent coronary artery ligation. g Sections of the heart of Treg-injected mice,
showing EdU incorporation (stained red) in the nuclei of CMs (stained green by anti-PCM1 antibodies). Nuclei are stained in blue with DAPI. Scale bar, 10
μm. h Section of the heart showing injected Tregs (labeled in white by anti-EGFP antibodies) in proximity of one EdU+ CM (EdU is labeled in red and CMs
in green by anti-α-actinin antibodies). Nuclei are stained in blue with DAPI. Scale bar, 50 μm. All values are mean ± s.e.m. each dot indicates a biological
replicate. Pairwise comparison was performed with the Student’s t-test (b, f). Two-way ANOVA for repeated measurements was used in (c, d). *P < 0.05,
**P < 0.01, relative to control
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indicated a significant reduction of infarct size at day 15 (22% and
35% reduction in the AAV9-Pool6 and AAV9-Pool12 groups,
respectively; P < 0.05 in both cases, as determined by one-way
analysis of variance and Bonferroni post hoc test). This reduction
remained stable at day 60 (22% and 34% reduction in the AAV9-
Pool6 and AAV9-Pool12 groups, respectively; P < 0.05 in both
cases, as determined by one-way analysis of variance and
Bonferroni post hoc test), as shown by a few representative
hearts in Fig. 6c. These pathological observations correlated with
significantly improved cardiac function in the animals treated
with the two AAV pools. Left ventricle ejection fraction and
fractional shortening were improved through the whole echo-
cardiographic follow-up period, with the most beneficial effect
evident at the latest time point (Fig. 6d, e). Analogous results were
obtained analyzing other parameters of cardiac function, includ-
ing left ventricle anterior wall systolic thickness (LVAWs) and left
ventricle systolic internal diameter (LVID), the main indicator of
cardiac dilation and dysfunction (Supplementary Fig. 10a, b).
Analysis of CM proliferation revealed a significant increase in
the number of CMs undergoing DNA synthesis (number of EdU
+/α-actinin+ cells: 0.2 ± 0.1% in control, 0.6 ± 0.3% in AAV9-
Pool6, and 0.8 ± 0.3% in AAV9-Pool12 animals), as shown in
Fig. 6f. In AAV9-Pool12 we also detected the presence of PCM1+
nuclei scoring positive for H3PS10, indicating cell cycle
progression to late G2/mitosis (Supplementary Fig. 10c).
Thus, soluble factors secreted by Tregs reduce infarct size,
preserve cardiac function and promote CM proliferation after
myocardial infarction.
Discussion
Collectively, the results shown here indicate that CD4+Foxp3+
Tregs act in a paracrine manner to promote CM proliferation
during development, in both the maternal and the embryonic
heart, and after myocardial infarction. They also show that a pool
of key factors is responsible for this mitogenic activity in cultured
cells and in vivo.
It is well established that an expansion of the Treg compart-
ment occurs during pregnancy. In mice, a monthly increase in
Tregs within the uterus during the estrus cycle prepares the uterus
for a potential embryo implantation. If the implantation occurs,
the expansion continues, first involving only thymus-derived
Tregs and then also involving peripherally induced Tregs,
reaching the highest level when trophoblast invasion to decidua is
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whereas only those exerting a pro-proliferative effect individually were included in Pool6. Black bars correspond to proteins included in Pool6, whereas gray
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control vector, AAV-Pool6, and AAV-Pool12, showing EdU incorporation (stained red) in the nuclei of CMs (stained green). Nuclei are stained blue with
DAPI. Scale bar, 50 μm. All values are mean ± s.e.m., each dot indicates a biological replicate. One-way analysis of variance and Bonferroni/Dunn’s post
hoc tests were used to compare multiple groups in a. Two-way ANOVA for repeated measurements was used in (d). *P < 0.05, **P < 0.01, relative to
control
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maximal (2nd semester in human and E12–14 in mice)19,20.
Although these events have been so far correlated to the regula-
tion of the maternal immune response against feto-placental graft
in the uterus, it is reasonable that these cells might affect other
organs in both the fetal and the maternal body. Our results
support this hypothesis as they show a direct effect of Tregs on
CMs, independent of their immune modulatory function. Indeed,
the supernatant of cultured Tregs was able to stimulate DNA
proliferation and cytokinesis on primary CMs and Treg-depletion
in vivo resulted in reduced CM proliferation in the developing
embryonic heart. Of notice, we also showed that a certain rate of
CM proliferation also occurs in the heart of pregnant mice, at
least in part as a consequence of Treg expansion, as Treg-
depletion in pregnant mice resulted in a reduced number of
proliferating CMs. This reduction was not statistically significant,
likely because Treg depletion was started at E10, in order to
minimize the risk of resorption, and CM proliferation was
assessed at its peak (E12), when the efficiency of depletion was
still low. These data, however, open a window of novelty on the
pathophysiology of the increased cardiac size always observed
during pregnancy and traditionally called physiological hyper-
trophy to refer to the phenotypic gross similarities with patho-
logical hypertrophy, which is the consequence of hypertension,
myocardial infarction, valvular heart diseases, or genetic muta-
tions. While physiological hypertrophy, which also occurs upon
exercise, is characterized by normal or even enhanced contractile
function coupled with normal architecture and cardiac structure,
pathological hypertrophy associates with CM death and fibrotic
remodeling, and is characterized with reduced systolic and dia-
stolic function, often progressing toward heart failure. Among the
triggering events of cardiac hypertrophy, mechanical stress and
neurohormonal stimulation are considered of primary impor-
tance in both cases. In pathological conditions, the hypertrophy
of the left ventricle appears to be beneficial in the short-term and
detrimental in the long-term harm21, however, the exact
mechanisms regulating the transition from adaptive to mala-
daptive hypertrophy are yet to be determined. Our data indicate
that Tregs are recruited to the heart during pregnancy and early
after myocardial infarction, two conditions considered to provide
compensatory benefit and preserve heart function. These data
tend to suggest that in both instances they could contribute to
enhance cardiac contractility not only through the induction of
CM enlargement but also through the stimulation of their
proliferation.
In agreement with this concept, CM cross-sectional area sig-
nificantly increased at the end of the pregnancy, but was rather
stable at the earliest time point (E12), when the heart weight
appeared modestly but already increased. At the same time point,
both Treg number in the peripheral blood and the number of
EdU+ CM reached their highest values. At the same time point, a
few AuroraB+ CMs could also be observed, suggesting that a
round of CM hyperplasia, followed by hypertrophy, could be
responsible for the increased cardiac size during pregnancy.
Other reports have previously shown a beneficial effect of Tregs
on heart function, especially after myocardial infarction. This
effect has been so far ascribed to the capacity of Tregs to favorably
interfere with cardiac remodeling, by inhibiting the production of
pro-inflammatory cytokines10 and inducing an M2-like macro-
phage differentiation, associated with myofibroblast activation
and expression of macrophage-derived proteins fostering myo-
cardial healing11. Our data confirm an essential and beneficial
role of Tregs after acute heart ischemia, as their depletion in vivo
determined a net increase in infarct size, reasonably due to the
increased number of inflammatory cells at the level of the scar,
often resulting in aneurysm formation and cardiac rupture. At the
same time, our findings indicate that Tregs might protect the
heart through an additional, previously unnoticed mechanism,
namely by secreting proteins able to stimulate CM proliferation.
Our data add to the now growing list of Treg functions, which
extend far beyond immune regulation. For instance, Tregs located
within the visceral adipose tissue control glucose uptake by cul-
tured adipocytes6, while in the skeletal muscle they enhance the
colony-forming efficiency of satellite cells and promote muscle
repair7. Of interest, Tregs act in a paracrine manner to potentiate
muscle repair, essentially through the secretion of the growth
factor Amphiregulin, which is able to induce the myogenic dif-
ferentiation of culture satellite cells and also to restore the muscle-
specific reparative capacity, otherwise lost in Treg-depleted mice7.
Our results are in line with the capacity of Tregs to promote the
regeneration of other cell types in a paracrine manner, as the
proliferative activity of Tregs on both cultured CMs and in vivo
appears to be largely mediated by a pool of secreted proteins,
abundantly secreted by Tregs compared to CD4+/CD25− T
lymphocytes. While there is no direct evidence that maternal
Tregs can cross the placenta, (i) they have been found in the fetal
lymph nodes and (ii) they produce cytokines that can cross the
placenta and reach the fetal heart. Among these, six secreted
proteins (Cst7, Tnfsf11, Il33, Fgl2, Matn2, and Igf2) were able to
stimulate CM proliferation individually. Of notice, all these
proteins have been shown to promote the proliferation of other
cell types, in particular cancer cells, and a few of them have been
implicated in other regenerative processes. Cystatin F (Cst7) is a
member of the cystatin super-family and is predominantly
expressed by the cells of the hematopoietic lineage, as well as by
metastatic cancerous cells, although it is not yet clear whether it
favors seeding, survival or proliferation of tumor cells at sec-
ondary sites (mainly liver and spleen)22,23. TNF superfamily
member 11 (Tnfsf11), or RANKL, is a member of the tumor
necrosis factor (TNF) cytokine family, which is a ligand for
osteoprotegerin and functions as a key factor for osteoclast dif-
ferentiation and activation. It is also a key paracrine effector of
progesterone signaling, which importantly contribute to mam-
mary tumorigenesis24. Interleukin-33 (Il33)—a member of the IL-
1 family—was originally described as an inducer of type 2
immune responses, activating T helper 2 cells and mast cells.
More recently, evidence has accumulated that this factor is more
pleiotropic in nature, bridging innate and adaptive immunity in
the regulation of tissue homeostasis, injury and repair25. The
interaction between Il33 and its membrane receptor ST2L is
enhanced in response to myocardial stress and exerts cardio-
protective actions in the myocardium by reducing fibrosis and
hypertrophy. In accordance, the circulating, soluble isoform of
the receptor (sST2), by sequestering Il33, abrogates these favor-
able activities and is currently considered among the potential
biomarkers for heart failure26. Although a direct activity of Il33 in
enhancing cardiomyocyte proliferation has never been
reported so far, its capacity to foster the growth and metastatic
invasion of at least some cancer types, including non-small-cell
lung cancer (NSCLC)27, epithelial ovarian cancer28, breast
cancer29, and glioma30. Fibrinogen-like 2 (Fgl2), also known as
fibroleukin, is an additional multifunctional protein, involved in a
variety of physiological and pathological processes, including viral
infections, pregnancy failure, autoimmune disorders, allograft
rejections, and tumor growth31. While inhibiting T cell pro-
liferation in various contexts32, it contributes to hepatocellular
carcinoma (HCC) tumor growth and angiogenesis33 in a
thrombin-dependent manner, thus indicating that its activity
in vivo strictly depends on target cells and local microenviron-
ment. Matrilin2 (Matn2) is the largest member of the matrilin
family of multidomain adapter proteins, which interact with other
extracellular matrix proteins to form filamentous networks by
connecting proteoglycans and collagen fibrils34. Matn2 forms
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oligomers, which are deposited in connective tissues of almost
any organ and is required for both peripheral nerve35 and muscle
regeneration36. Of interest, in the muscle Matn2 is deposited
around proliferating, differentiating, and fusing myoblasts in
culture and during muscle regeneration in vivo, where it plays a
key role in regulating the cascade that initiated terminal myogenic
differentiation36. Whether a similar mechanism may occur dur-
ing mammalian heart regeneration is an interesting possibility,
which deserves further investigation. Insulin-like growth factor 2
(IGF2) is a protein hormone known to regulate cell proliferation,
growth, migration, differentiation, and survival. Beside its
growth-promoting and beneficial functions during embryonic
development and placental growth, a role for IGF2 has been
clearly established in both cancer and cardiovascular diseases37.
Even though data are not always consistent, IGF2 has been shown
to act in an autocrine or paracrine fashion to promote the growth
of a variety of neoplasia, including brain tumors, mammary
carcinoma, pancreatic carcinoma, and ovarian carcinoma37. It
also acts as a pivotal promoter of growth of atherosclerotic lesions
in mice and its local overexpression induces smooth muscle
proliferation and the appearance of aortic focal intimal masses38.
Thus, any of these six factors appears able to exert a pro-
proliferative effect on various cell types. Our data do not prove
the necessity of these factors in mediating the capacity of Tregs to
stimulate CM proliferation. However, the administration of AAV
vectors expressing the pool of Treg-specific pro-proliferative
cytokines recapitulated both the beneficial effect on heart func-
tion following myocardial infarction and incorporation of EdU by
CMs, thus pointing toward these six factors as relevant players in
the beneficial effect of Tregs on the damaged heart.
Methods
Isolation and culture of neonatal and adult cardiomyocytes. Neonatal cardio-
myocytes were isolated and cultured from p0-p1 old pups by enzymatic diges-
tion15. Briefly, ventricles from neonatal rats were separated from the atria and
enzymatically dissociated and digested in CBFHH basal buffer (calcium and
bicarbonate-free Hanks buffer with Hepes) containing Trypsin (1.8 mg/ml, Gibco),
DNAse II (2 mg/l, Sigma Aldrich), and Gentamicin (1%, Sigma Aldrich) for 3 h at
37 °C under gentle agitation. Trypsin activity was stopped by adding 8 ml of fetal
bovine serum (FBS) to the collected cells. The solution was centrifuged for 10 min
at 300×g, and the re-suspended pellet filtered through a 40-μm cell strainer (BD
Biosciences) before seeding. Cardiomyocytes were enriched (>90% purity) over
non-myocytes by a 2-h pre-plating step on non-primary 100-mm dishes in com-
plete medium (DMEM 4.5 g/L of D-Glucose, Gibco), supplemented with 5% FBS
(Gibco), 2 mg/ml vitamin B12 (Sigma Aldrich), 100 U/ml penicillin, and 100 U/ml
streptomycin (Sigma Aldrich). Myocytes, either in solution or lightly attached, were
separated from the stromal cells by gentle mechanical disaggregation, counted, and
subsequently plated on primary plates at a density of 1.5 × 105 cells/ml. After 24 h,
the medium was changed and cells were subjected to the different treatments.
Adult cardiomyocytes were isolated and cultured according to a Langendorff-free
procedure39. All experimental conditions were tested in triplicate on at least three
independent cell cultures.
Cell proliferation was evaluated by administration of EdU (10 mM, Life
Technologies) for 20 h when testing proliferation in CMs only (Figs. 1 and 6) and
for 10 h when also testing proliferation in fibroblasts (Fig. 2), followed by washing,
fixation and immunofluorescence staining.
Isolation and culture of Tregs. Tregs were isolated from mesenteric, axillary,
inguinal, and cervical lymph nodes using the CD4+CD25+ Regulatory T Cell
Isolation Kit (Miltenyi Biotec), using a two-step procedure. First, non-CD4+ cells
were magnetically labeled with a cocktail of biotin-conjugated antibodies against
CD8, CD11, CD45R, CD49b, Ter-119, and Anti-Biotin MicroBeads. The labeled
cells were subsequently depleted using a MACS LS column (Miltenyi Biotec). In the
second step, the flow-through fraction of pre-enriched CD4+ T cells was labeled
with CD25 MicroBeads for subsequent positive selection of CD4+CD25+ Tregs.
Isolated cells were counted and seeded into 96-well round bottom plates, previously
activated overnight at 4 °C with an anti-mouse CD3 antibody in PBS (1:1000,
Invitrogen) and cultured in RPMI-1640 supplemented with 100 U/ml penicillin,
100 μg/ml streptomycin, 10% FBS, and recombinant murine IL2 (50 ng/ml). The
supernatants produced by Treg cells were recovered at 24–48–72 h and stored at
−80 °C.
Animal studies. Animal care and treatment were conducted in conformity with
institutional guidelines in compliance with national and international laws and
policies (European and Economic Council Directive 86/609, OJL 358, December
12, 1987), upon approval by the ICGEB Institutional Animal Welfare Board and by
the Italian Ministry of Health. CD1, athymic nude Foxn1, Fox Chase SCID, and
Fox Chase SCID BEIGE mice were purchased from Harlan Laboratories. EGFP
(C57BL/6-Tg(CAG-EGFP)1Osb/J) mice were purchased from The Jackson
Laboratory). DEREG40,41 and Collα1(I)-EGFP mice42 were bred in house. A block
randomization scheme was used to assign animals to groups on a rolling admis-
sions basis to obtain adequate samples for each time point and each experiment.
To assess CM proliferation in vivo animals received EdU (350 µg per animal,
intraperitoneally) every 2 days for the indicated time periods.
Blood was drawn from the jugular vein of anesthetized animals and allowed to
clot at 37 °C for 2 h, followed by centrifugation at 200×g for 10 min at 4 °C. Sera
were immediately transferred into a new tube with the addition of 100 U/ml
penicillin and 100 g/ml streptomycin to avoid bacterial contamination and stored
at −20 °C until use.
Myocardial infarction. Mice (2-month-old female animals, n= 8 per group) were
anesthetized by intraperitoneal injection of ketamine–xylazine and laid down in a
supine position on a dedicated pad at 37 °C, fixed to the plate and intubated. To
reach the anterior wall of the heart, a xifo-axillar incision was made, exposing the
underlying muscles. The pectoralis major muscle was lifted up and fixed with a
retractor, while the underlying pectoralis minor was cut to expose the ribs. The fifth
intercostal space was pierced and enlarged with a retractor opening the thorax. The
pericardium was stripped exposing the heart anterior wall. The left anterior des-
cending coronary artery was identified and ligated 1 mm below the left atrium
auricula. Effective ligation of the coronary artery was confirmed by whitening of
the heart anterior wall. Ligation was either left in place permanently or removed
after 40 min to allow reperfusion after ischemia. All treatments (Tregs and AAV-
pools) were injected into the left ventricle anterior wall, at the border region of the
infarct, using a 0.3 ml insulin syringe with a 30-gauge needle. All anatomical
structures were visualized with a stereomicroscope (Leica). Intercostal spaces,
muscles and skin were sutured and mice were extubated to re-establish normal
breathing. Mice were then laid in a prone position and kept on the warmed pad
until awakening and later transferred to a new cage.
To evaluate heart function and size, transthoracic two-dimensional
echocardiography was performed in mice anaesthetized with isoflurane keeping the
heart rate over 450 bpm, using a Vevo 2100 Ultrasound (Visual Sonics) equipped
with a MS550D 22–50MHz linear array solid-state transducer. B-mode multi-
planar tracings in parasternal short and long axis views (modified Simpson’s
method) were used to measure left ventricular anterior and posterior wall
thickness, septum thickness and left ventricular internal diameter at end-systole
and end-diastole, which were used to calculate left ventricular fractional shortening
and ejection fraction.
Treg depletion. For depletion experiments, purified anti-CD25 monoclonal anti-
bodies (clone PC61, ATCC, 1 mg per mouse) were injected intraperitoneally into
CD1 mice. Alternatively, diphtheria toxin (Calbiochem, 500 ng per mouse) was
administered intraperitoneally once a week in DEREG mice. Efficacy of depletion
was assessed in mesenteric, axillary, inguinal, and cervical lymph nodes by flow
cytometry.
Flow cytometry and cell sorting. For Treg staining and cell sorting, cells were
analyzed using either a BD FACSCalibur or a FACS Aria II (BD), incubating cells
on ice for 30 min in PBS and 2% BSA with PE-conjugated anti-CD25 antibodies
(clone 7D4, Miltenyi Biotec #130102788) or PerCP-conjugated anti-CD4 (clone
RM4-5, BD Pharmingen #553052) antibodies (1:100 dilution for both). Analysis of
flow cytometry data was performed using FlowJo (version 4.5.4; Tree Star). Isotype
controls were performed with corresponding rat Ig.
Immunofluorescence and histology. Immunofluorescence was performed on
both tissue sections and plated cells. After euthanasia, mouse hearts were excised,
briefly washed in PBS and either fixed in 10% formalin at room temperature or
snap frozen in isopentane/liquid nitrogen. Formalin-fixed tissues were embedded
in paraffin and cut into 4 µm tissue sections, de-waxed in xylene for 30 min and
rehydrated with alcohols at decreasing concentration (100, 90, 70, 50%) at room
temperature. Antigen retrieval was performed on sections by boiling 20 min in 0.1
M sodium citrate buffer solution at pH 6.0 and letting cool down at room tem-
perature for 3 h. Sections were rinsed three times in water, permeabilized 30 min in
0.5% Triton X-100 PBS, and then blocked for 1 h in 20% horse serum PBS. Cells
were grown on gelatin–fibronectin-coated cover slips and fixed in 4% paraf-
ormaldehyde for 15 min at room temperature.
All samples were washed three times in PBS, permeabilized in 0.5% Triton 100-
X for 30 min, and blocked in 10% goat serum for 1 h. Sections were stained
overnights at 4 °C with the following antibodies: anti-PCM1 (Sigma Aldrich
#HPA023374), anti-sarcomeric α-actinin (Abcam #9465), anti-aurora B (Abcam
#2254), anti-phospho-histoneH3-Ser10 (Millipore #06-570), anti-Ki-67 (Monsan
#PSX1028), anti-EGFP (Abcam #6658), anti-CD45 (BD Pharmingen # 550539), all
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1:100 in 5% goat serum. After two washing steps of 5 min in 0.5% Triton X-100 at
room temperature, sections were incubated 1 h in 1:200 secondary antibody
conjugated to Alexa Fluor-488 or Alexa Fluor-594 (Life Technologies) in 10% goat
serum for 45 min at room temperature. EdU was detected using the Click-iT EdU
Alexa Fluor® 594 Imaging Kit (Invitrogen). Nuclei were stained with a 0.1 mg/ml l
of 4′, 6-diamidino-2-phenylindole dihydrochloride (DAPI) solution (Sigma).
Azan-Mallory’s trichrome staining (Bio Optica) was performed according to
standard procedures and analyzed for morphology and extension of fibrosis. Infarct
size was calculated as the percentage of the total left ventricular area showing
fibrosis.
TUNEL assay. Myocardial apoptosis was examined using the In Situ Cell Death
Detection Kit, TMR red (Roche). Briefly, 5 μm-thick heart sections were incubated
with the labeling mixture supplied by the manufacturer at 37 °C for 1 h. Cell nuclei
were counterstained with Hoechst 33342 (Invitrogen). Three slides from each block
were evaluated for percentage of apoptotic cells and four fields on each slide were
examined at the border areas. The number of apoptotic CMs is presented as a
percentage of total CMs.
RNA isolation and quantitative real-time PCR. Total RNA was extracted using
TRIzol (ThermoFisher) and reverse transcribed using hexameric random primers.
The amplifications were performed on a BioRad Real-time thermal cycler CFX96
machine, using the following TaqMan probes (Applied Biosystems): mTNFα
Mm00443258_m1, mMMP9 Mm00442991_m1, mTGFβ1 Mm01178820_m1,
mFoxp3 Mm00475162_m1, mIL10 Mm00439614_m1, mIL6 Mm00446191_m1,
mIFNγ Mm01168134_m1, and mIl12p40 Mm01288989_m1. The murine house-
keeping GAPDH gene (mGAPDH Mm99999915_g1) was used to normalize the
results.
CHO cell transfection and supernatant collection. Chinese Hamster Ovary
(CHO) cells were cultured in F12 medium (F12 Nutrient Mixture, Thermo Fisher
Scientific) supplemented with 10% FBS (GIBCO), L-glutamine 2 mM, 100 U/ml
penicillin (Sigma Aldrich) and 100 μg/ml streptomycin (Sigma Aldrich).
Transfection was carried out in 24-well plates using Lipofectamine 2000
(Invitrogen, Thermo Fisher Scientific). Cells were transfected with 0.4 μg plasmid
DNA in a 1:2 μg DNA: μl Lipofectamine ratio. After 24 h, cells were washed to
remove FBS and kept in serum-free medium for additional 24 h. Supernatants
produced by the transfected cells were collected, centrifuged to remove any cell and
stored at −80 °C. The list of plasmids encoding for the soluble factors expressed by
Tregs is reported in Table 1.
AAV production. Recombinant AAV vectors were prepared in the AAV Vector Unit
at ICGEB Trieste, (www.icgeb.org/avu-core-facility)43. Briefly, AAV vectors were
generated in HEK293T cells, using a triple-plasmid co-transfection for packaging.
Viral stocks were obtained by CsCl2 gradient centrifugation. Titration of AAV viral
particles was performed by real-time PCR quantification of the number of viral
genomes. The viral preparations had titers between 2 × 1012 and 3 × 1013 vg/ml.
Statistics. Data are expressed as the mean of biological replicates, and error given
as standard error of the mean. Statistical analysis was performed using the SPSS
software considering a P-value of less than 0.05 as statistically significant. For his-
tological analysis and gene expression data at a single time point, the statistical
significance of the differences between groups was determined using the unpaired t
test. For morphological and functional scores among the time points within each
group and among the groups within each time point we used two-way anova for
repeated measurements, followed by Tukey’s pairwise post-hoc test or Bonferroni/
Dunn’s post-hoc test. An F-test was used to compare variance. For in vivo
experiments, a statistical design of the sample size was performed using the software
http://homepage.stat.uiowa.edu/~rlenth/Power/, setting a variation coefficient (s) of
30%, a minimal relative effect (δ) of 30%, alpha of 5%, and a power of 80% (p).
Data availability. All data generated or analyzed during this study are included in
this article and its supplementary information files. The transcriptome of
CD4+/CD25+ Tregs with that of CD4+/CD25- lymphocytes was derived from the
GEO database (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE4571).
All relevant data are available from the authors upon reasonable request.
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